| Characteristic |
ADALIMUMAB, N = 17,411 |
AZATHIOPRINE, N = 16,932 |
BALSALAZIDE, N = 1,406 |
BUDESONIDE, N = 10,020 |
CERTOLIZUMAB, N = 1,170 |
CYCLOSPORINE, N = 537 |
DEXAMETHASONE, N = 14,959 |
GOLIMUMAB, N = 320 |
INFLIXIMAB, N = 90,506 |
MERCAPTOPURINE, N = 2,388 |
MESALAMINE, N = 25,640 |
METHOTREXATE, N = 5,125 |
METHYLPREDNISOLONE, N = 14,393 |
NATALIZUMAB, N = 6 |
OLSALAZINE, N = 8 |
OZANIMOD, N = 2 |
PREDNISOLONE, N = 512 |
PREDNISONE, N = 28,975 |
research, N = 721 |
RISANKIZUMAB, N = 3 |
SULFASALAZINE, N = 5,112 |
TOFACITINIB, N = 1,678 |
UPADACITINIB, N = 36 |
USTEKINUMAB, N = 10,516 |
VEDOLIZUMAB, N = 26,367 |
| order_status |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CANCELED |
1,902 (12%) |
1,107 (7.1%) |
76 (6.9%) |
638 (6.9%) |
262 (24%) |
12 (2.4%) |
3,189 (22%) |
137 (45%) |
46,651 (53%) |
201 (9.4%) |
1,466 (6.5%) |
408 (9.0%) |
3,166 (22%) |
0 (0%) |
0 (NA%) |
0 (0%) |
15 (3.4%) |
1,378 (5.3%) |
339 (51%) |
0 (0%) |
345 (7.5%) |
128 (8.1%) |
5 (16%) |
3,491 (35%) |
14,567 (57%) |
| COMPLETED |
432 (2.7%) |
33 (0.2%) |
0 (0%) |
22 (0.2%) |
148 (14%) |
11 (2.2%) |
8,341 (56%) |
99 (33%) |
39,533 (45%) |
9 (0.4%) |
70 (0.3%) |
248 (5.5%) |
5,078 (36%) |
2 (67%) |
0 (NA%) |
0 (0%) |
40 (9.1%) |
961 (3.7%) |
226 (34%) |
0 (0%) |
11 (0.2%) |
24 (1.5%) |
1 (3.1%) |
1,413 (14%) |
10,282 (41%) |
| DISCONTINUED |
264 (1.7%) |
1,799 (11%) |
126 (11%) |
1,077 (12%) |
68 (6.3%) |
239 (48%) |
2,138 (14%) |
9 (3.0%) |
1,215 (1.4%) |
108 (5.1%) |
3,077 (14%) |
113 (2.5%) |
4,467 (32%) |
1 (33%) |
0 (NA%) |
0 (0%) |
129 (29%) |
5,092 (20%) |
72 (11%) |
0 (0%) |
591 (13%) |
211 (13%) |
15 (47%) |
125 (1.3%) |
151 (0.6%) |
| DISPENSED |
1 (<0.1%) |
315 (2.0%) |
0 (0%) |
2 (<0.1%) |
0 (0%) |
47 (9.4%) |
412 (2.8%) |
0 (0%) |
28 (<0.1%) |
0 (0%) |
53 (0.2%) |
0 (0%) |
809 (5.7%) |
0 (0%) |
0 (NA%) |
0 (0%) |
16 (3.6%) |
1,007 (3.9%) |
24 (3.6%) |
0 (0%) |
0 (0%) |
1 (<0.1%) |
0 (0%) |
26 (0.3%) |
25 (<0.1%) |
| SENT |
13,018 (82%) |
12,109 (77%) |
883 (80%) |
7,168 (78%) |
597 (55%) |
180 (36%) |
654 (4.4%) |
58 (19%) |
1,012 (1.1%) |
1,774 (83%) |
17,503 (78%) |
3,665 (81%) |
526 (3.7%) |
0 (0%) |
0 (NA%) |
2 (100%) |
222 (50%) |
15,932 (62%) |
3 (0.5%) |
1 (100%) |
3,562 (78%) |
1,185 (75%) |
11 (34%) |
4,827 (48%) |
299 (1.2%) |
| SUSPEND |
325 (2.0%) |
314 (2.0%) |
15 (1.4%) |
283 (3.1%) |
11 (1.0%) |
12 (2.4%) |
50 (0.3%) |
1 (0.3%) |
85 (<0.1%) |
40 (1.9%) |
408 (1.8%) |
110 (2.4%) |
20 (0.1%) |
0 (0%) |
0 (NA%) |
0 (0%) |
18 (4.1%) |
1,456 (5.6%) |
2 (0.3%) |
0 (0%) |
73 (1.6%) |
31 (2.0%) |
0 (0%) |
93 (0.9%) |
61 (0.2%) |
| VERIFIED |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
39 (0.3%) |
0 (0%) |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
0 (0%) |
8 (<0.1%) |
0 (0%) |
0 (NA%) |
0 (0%) |
0 (0%) |
2 (<0.1%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
| (Missing) |
1,469 |
1,255 |
306 |
830 |
84 |
36 |
136 |
16 |
1,981 |
256 |
3,062 |
581 |
319 |
3 |
8 |
0 |
72 |
3,147 |
55 |
2 |
530 |
98 |
4 |
541 |
982 |